Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
In over ten years since our inception, Moderna has transformed from an infectious disease-focused company advancing programs in the field mRNA to a company with a diverse portfolio of vaccines and therapeutics across seven modalities.
In over ten years since our inception, Moderna has transformed from an infectious disease-focused company advancing programs in the field #mRNA to a company with a diverse portfolio of #vaccines and #therapeutics across seven modalities. pic.twitter.com/uz4Et3VhjU
— Moderna (@moderna_tx) October 25, 2022
CDC has altered their view and comments about the effectiveness of TPOXX. Their website, updated on Oct 18, now reads:
"While monkeypox symptoms can resolve on their own, treatment for orthopoxviruses is available and can provide relief and decrease disease severity for persons with monkeypox. The treatment is tecovirimat (TPOXX), available as a pill or intravenous (IV) infusion. At this time, TPOXX is available through state and territorial health departments and CDC."
https://www.cdc.gov/poxvirus/monkeypox/health-departments/intervention-services.html
Moderna CEO On Where We Are In The Pandemic
You know, we have $17 billion of cash, so we're investing that capital to grow a platform to make more products – we have now 46 drugs in development that's 46.
https://www.valuewalk.com/moderna-ceo-on-where-we-are-in-the-pandemic/
EMA COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE ISSUES POSITIVE OPINION RECOMMENDING AUTHORIZATION FOR THE USE OF SPIKEVAX (MRNA-1273) IN CHILDREN 6 MONTHS - 5 YEARS IN THE EUROPEAN UNION
https://investors.modernatx.com/news/news-details/2022/EMA-Committee-for-Medicinal-Products-for-Human-Use-Issues-Positive-Opinion-Recommending-Authorization-for-the-Use-of-Spikevax-mRNA-1273-in-Children-6-Months---5-Years-in-the-European-Union/default.aspx
IN CENTRAL AFRICA, A DEADLY MONKEYPOX VARIANT IS SURGING
https://www.nationalgeographic.co.uk/science-and-technology/2022/10/in-central-africa-a-deadly-monkeypox-variant-is-surging/amp
New York and Nevada report first monkeypox deaths
https://news.yahoo.com/u-monkeypox-deaths-rise-4-184822233.html
EMA COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE ADOPTS POSITIVE OPINION RECOMMENDING AUTHORIZATION OF MODERNA'S OMICRON BA.4-BA.5 TARGETING BIVALENT COVID-19 VACCINE IN THE EUROPEAN UNION
https://investors.modernatx.com/news/news-details/2022/EMA-Committee-For-Medicinal-Products-For-Human-Use-Adopts-Positive-Opinion-Recommending-Authorization-Of-Modernas-Omicron-BA.4-BA.5-Targeting-Bivalent-Covid-19-Vaccine-In-The-European-Union/default.aspx
Mass General Brigham studying whether antiviral tecovirimat helps treat monkeypox
https://www.bostonherald.com/2022/10/19/mass-general-brigham-studying-whether-antiviral-tecovirimat-helps-treat-monkeypox/
90-DAY ANALYSIS SHOWS MODERNA’S OMICRON BA.1-TARGETING BIVALENT VACCINE, MRNA-1273.214, DEMONSTRATES SUPERIOR ANTIBODY RESPONSE AS FOURTH BOOSTER COMPARED TO SPIKEVAX PROTOTYPE BOOSTER
https://investors.modernatx.com/news/news-details/2022/90-Day-Analysis-Shows-Modernas-Omicron-BA.1-Targeting-Bivalent-Vaccine-mRNA-1273.214-Demonstrates-Superior-Antibody-Response-as-Fourth-Booster-Compared-to-Spikevax-Prototype-Booster/default.aspx
"Moderna is estimated to be selling vials for between $32 - $50 with the United States potentially paying even more. Moderna indicated that the potential prices in the U.S. market could range from $64 to $100 per dose," the report said.
This comes while even more competitors come online, but according to the report, still won't be able to penetrate at the level Moderna and Pfizer.
Moderna CEO talks competition with J&J, Novavax, AstraZeneca
https://finance.yahoo.com/video/moderna-ceo-talks-competition-j-150917018.html
Moderna CEO: Not everyone will need an annual COVID booster
https://finance.yahoo.com/news/moderna-ceo-not-everyone-will-need-an-annual-covid-booster-161914016.html
Chris Harvey from Wells Fargo investing was just on CNBC and had asModerna pick of his 5 stock plays.!
https://www.cnbc.com/video/2022/10/17/bear-market-rally-has-further-upside-says-wells-fargos-chris-harvey.html
More contagious new COVID variant: After Kerala, Maharashtra issues fresh alerts
https://www-livemint-com.cdn.ampproject.org/v/s/www.livemint.com/news/india/more-contagious-new-covid-variant-after-kerala-maharashtra-issues-fresh-alerts/amp-11666050894530.html?amp_js_v=a6&_gsa=1&usqp=mq331AQIKAGwASCAAgM%3D#aoh=16660645931600&csi=0&referrer=https%3A%2F%2Fwww.google.com&_tf=Da%20%251%24s&share=https%3A%2F%2Fwww.livemint.com%2Fnews%2Findia%2Fmore-contagious-new-covid-variant-after-kerala-maharashtra-issues-fresh-alerts-11666050894530.html
Moderna CEO on developing a vaccine ‘franchise’ for COVID, flu, HIV
https://finance.yahoo.com/video/moderna-ceo-developing-vaccine-franchise-145757007.html
"stay tuned" The Phase 2 trial is fully enrolled and primary data are expected in the fourth quarter of 2022..." We are in the 4th quarter of '22.
cancer vaccine mRNA-4157.....Under the agreement, originally established in 2016 and amended in 2018, Merck will pay Moderna $250 million to exercise its option for personalized cancer vaccines including mRNA-4157/V940 and will collaborate on development and commercialization.The payment willbe expensed by Merck in the third quarter of 2022 and included in its non-GAAP results. Merck and Moderna will share costs and any profits equally under this worldwide collaboration.
After this year is over moderna will have more cash than 98% of biotech and pharma companies.......Oh and no debt to speak of >>>>>>>>>>>>>
June 29, 2016. https://www.genengnews.com/topics/omics/merck-moderna-to-develop-mrna-based-personalized-cancer-vaccines/
Through this collaboration with Merck, we are now well-positioned to accelerate research and development with a goal of entering the clinic in 2017, as well as to apply our unique GMP manufacturing capabilities to support the rapid production of these highly individualized vaccines,” Moderna CEO Stéphane Bancel said in a statement. “Our team has made significant progress since beginning our work in personalized cancer vaccines just last year. 2015"
you are not informed
That was a nice try, though. LOL
A top executive at one of China’s most prominent biotech companies said it was “mind-boggling” that Beijing had not allowed sales of Covid-19 vaccines using technology pioneered by Moderna and BioNTech/Pfizer.
https://www.ft.com/content/90d7d811-857d-4839-a9fc-9e68e5e4fe02
a 2week old infant....."A 2-week course of enteral tecovirimat (at a dose of 50 mg twice a day) was commenced in combination with intravenous cidofovir. After 4 weeks in intensive care, including 14 days of invasive ventilation, the infant recovered and was discharged home."
https://www.nejm.org/doi/full/10.1056/NEJMc2210828
A deadly new virus strongly resembling Ebola is about to spread to humans, according to a study published on September 30. This disease greatly worries scientists.
https://bsetours.com/shfv-virus-close-to-ebola-and-hiv-what-is-this-virus/
RELAX
PE is 4 way under value. Next 5 years growth rate is 13. Stock should trade at a Pe of 13
stay connected:
Under the agreement, originally established in 2016 and amended in 2018, Merck will pay Moderna $250 million to exercise its option for personalized cancer vaccines including mRNA-4157/V940 and will collaborate on development and commercialization.The payment willbe expensed by Merck in the third quarter of 2022 and included in its non-GAAP results. Merck and Moderna will share costs and any profits equally under this worldwide collaboration.
$MRNA MULTIBAGGER$$$$$$$$$$$
SIGA Provides Update on Progress in Clinical Trials
SIGA disclosed that the Company had received, as of mid September, approximately $76 million of international orders for oral TPOXX from twelve international customers.
https://investor.siga.com/news-releases/news-release-details/siga-provides-update-progress-clinical-trials-assess-use-tpoxx-r
And don't miss:
The Phase 2 trial is fully enrolled and primary data are expected in the fourth quarter of 2022.
is your thought. STOP
they are two different diseases!
Moderna exercises option to license proprietary targeting technology from Autolus
LONDON, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programed T cell therapies, today announces that Moderna (MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, has exercised its option to license Autolus’ proprietary binders against an undisclosed immuno-oncology target for the development and commercialization of mRNA therapeutics.
This follows an original agreement with Moderna announced on August 2, 2021, granting Moderna an exclusive option to license Autolus’ proprietary binders for up to four immuno-oncology targets for incorporation in certain mRNA therapeutics. On exercise of the option, Autolus has received an option exercise payment and is eligible to receive development and commercial milestone payments for each product successfully commercialized. In addition, Autolus would be entitled to receive royalties on net sales of all products commercialized under the agreement.
“The collaboration with Moderna has been a productive partnership, and it’s great to see this work progressing to the next stage,” said Dr. Martin Pule, CSO of Autolus. “The use of our technology in Moderna’s mRNA platform continues to underscore Autolus’ leadership in the development of innovative differentiated binder and cell programming technologies.”
https://finance.yahoo.com/news/moderna-exercises-option-license-proprietary-110000823.html
huge news cancer$$$$$$ The Phase 2 trial is fully enrolled and primary data are expected in the fourth quarter of 2022.
The investigational vaccine is currently being tested in a Phase 2 clinical trial as a treatment for patients with high-risk melanoma in combination with Merck’s Keytrduda, an anti-PD-1 therapy that has been approved to treat several types of cancer. It is Merck’s best-selling drug, with $5.2 billion in revenue in 2021.
mrna multibagger$$$$$
A capsule that tunnels through mucus in the GI tract could be used to orally administer large protein drugs such as insulin.
https://news.mit.edu/2022/protein-drugs-gi-tract-0928
There's a spike in respiratory illness among children — and it's not just COVID
Moderna's pivotal Phase 3 placebo-controlled clinical trial of mRNA-1345 RSV
The study has been designed to provide an efficacy readout in the 2022-2023 winter season.
https://www.npr.org/2022/10/11/1127873967/respiratory-illness-covid-children-hospitalizations-health
Roll-out of Moderna Spikevax bivalent Covid-19 vaccine brought forward to Oct 14
https://www.straitstimes.com/singapore/health/roll-out-of-moderna-spikevax-bivalent-covid-19-vaccine-brought-forward-to-oct-14
For decades, fear and failure in the hunt for an RSV vaccine. Now, success.
https://www.washingtonpost.com/health/2022/10/10/rsv-vaccine/
Respiratory Syncytial Virus Vaccine Program: Respiratory syncytial virus (RSV) causes a substantial disease burden in older adults aged 65 years and older. There are approximately 177,000 RSV-related hospitalizations in adults 65 and older in the U.S. each year and approximately 14,000 RSV-related deaths. Globally, there are more than 1.5 million episodes of acute respiratory tract infection related to RSV each year.
Moderna's pivotal Phase 3 placebo-controlled clinical trial of mRNA-1345, an RSV vaccine, will evaluate its effectiveness in older adults (adults 60 years of age and older); so far, the trial has enrolled more than 24,000 of the anticipated 34,000 participants. The study has been designed to provide an efficacy readout in the 2022-2023 winter season.
Since RSV also causes a significant disease burden in children, mRNA-1345 is being tested in an ongoing Phase 1 trial in pediatric populations.
Monkeypox: A dangerous variant circulating in the DRC could go global
https://www.newscientist.com/article/2341569-monkeypox-a-dangerous-variant-circulating-in-the-drc-could-go-global/
$SIGA
.... no doubt the result of early read outs on flu, cardiac therapies & skin cancer & solid tumors all in the time context of 3 to 12 months. the boom will start soon$$$$$$$$$$
https://www.skynews.com.au/australia-news/coronavirus/moderna-to-release-updated-booster-shot/video/903c0e8b5e383c12570476334c66488d
Q3 ended last week. At least $80m in sales compared to $9m reported Q2. Nov 4'ish should have the Q3 pr$$$$$$$$
The monkeypox virus is mutating. Are scientists worried
If health officials detect an uptick in the number of virus samples carrying these mutations, that could be a possible signal that they are helping the virus to spread.
The good news is that, although the monkeypox virus continues to evolve, no mutations have affected the part of its genome that encodes a protein targeted by tecovirimat, an antiviral drug being tested for use against monkeypox in humans.
https://www.nature.com/articles/d41586-022-03171-z
Scientists design and validate promising HIV vaccine strategy:
https://www.scripps.edu/news-and-events/press-room/2022/20220930-schief-hiv.html